Merck & Co Inc
6MK
Company Profile
Business description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Contact
126 East Lincoln Avenue
RahwayNJ07065
USAT: +1 908 740-4000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
75,000
Stocks News & Analysis
stocks
10 best US growth stocks to buy for the long term
The stocks of these high-quality growth companies look undervalued today.
stocks
Higher fair value for overvalued ASX tech share
Underlying secular growth stronger than we thought.
stocks
Nvidia: Collaboration with Intel might bring some goodwill with the US
We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,102.10 | 11.70 | 0.13% |
| CAC 40 | 7,843.74 | 9.85 | -0.13% |
| DAX 40 | 23,521.89 | 117.52 | -0.50% |
| Dow JONES (US) | 46,315.27 | 172.85 | 0.37% |
| FTSE 100 | 9,232.35 | 15.68 | 0.17% |
| HKSE | 26,344.14 | 200.96 | -0.76% |
| NASDAQ | 22,631.48 | 160.75 | 0.72% |
| Nikkei 225 | 45,493.66 | 447.85 | 0.99% |
| NZX 50 Index | 13,141.54 | 90.12 | -0.68% |
| S&P 500 | 6,664.36 | 32.40 | 0.49% |
| S&P/ASX 200 | 8,810.90 | 11.40 | 0.13% |
| SSE Composite Index | 3,828.58 | 8.49 | 0.22% |